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Abstract
Background: Immunocompromised patients, such as systemic lupus erythematosus (SLE) sufferers have an
increased risk of mortality, following influenza infection. In the recent pandemic, influenza A H1NI virus caused
18449 deaths, mainly because of adult respiratory distress syndrome or bacterial co-infections.
Case Presentation: In this case report, an SLE patient with viral-induced septic shock, without overt pulmonary
involvement, is discussed. The patient was administered oseltamivir and supportive treatment, including wide-
spectrum antibiotics, vasopressors and steroids, according to the guidelines proposed for bacterial sepsis and septic
shock. She finally survived and experienced a lupus flare soon after intensive care unit (ICU) discharge.
Conclusions: To our knowledge, this is the first case to report severe septic shock from influenza A/H1N1 virus,
without overt pulmonary involvement.
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Background
Infections are among the most important causes of mor-
bidity and mortality in systemic lupus erythematosus
(SLE). However, viruses are not considered to cause ser-
ious infections in these patients; they, usually, represent
reactivation of herpes viruses, such as herpes simplex virus
and varicella-zoster virus [1]. Nevertheless, it is reported
that immunocompromised patients have an increased risk
of mortality, following influenza infection [2].
In the recent pandemic, influenza A H1N1 virus has
been estimated to cause approximately 18.449 deaths in
214 different countries until August 1
st 2010 [3]. Adult
respiratory distress syndrome (ARDS), along with bacter-
ial co-infections were the direct causes of death in most
cases [4]. However, no cases of viral-induced septic shock
without severe pulmonary involvement have been
reported. Nevertheless, little is known about this infec-
tion in SLE patients [5]. Herein, we report a case of an
SLE patient, who developed septic shock due to influenza
A H1N1 infection, without acute lung injury.
Case Presentation
A 46-year old female was admitted to the hospital
because of low-grade fever, sore throat and fatigue for
four days; she was on clarithromycin 500 mg twice daily,
as she was considered to suffer from upper respiratory
tract infection by her general practitioner.
The patient had a history of SLE for 24 years, antipho-
spholipid syndrome and autoimmune hypothyroidism.
SLE was diagnosed in the background of immune throm-
bocytopenic purpura (ITP), starting at the age of 8. At
the age of 12, splenectomy was performed to control
refractory thrombocytopenia. Currently, SLE was ade-
quately controlled (Systemic Lupus Erythematosus Dis-
ease Activity Index, SLEDAI = 0, anti-dsDNA antibodies
negative, C3 and C4 levels normal); medication included
methylprednisolone 8 mg/day, azathioprine 50 mg/day,
aspirin 50 mg/day and levothyroxine 150 μg/day. The
patient had been vaccinated against seasonal influenza
and Streptococcus pneumoniae a month before, but not
against A/H1N1 virus.
On admission, she was in severe cardiovascular
instability with hypotension (BP = 60/40 mmHg), tachy-
cardia (HR = 130/min), tachypnea (RR = 30/min),
hypothermia (< 35.5°C), along with oliguria and altered
mental status. Oxygenation fraction PaO2/FiO2 was over
350. No obvious site of infection could be identified. The
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tomography of the thorax (Figure 1). Heart ultrasound
revealed mild diastolic dysfunction with preserved ejec-
tion fraction and no valvular disease. Concerning other
organ involvement, there was mild prerenal azotemia
(urea 94 mg/dl, creatinine 1.5 mg/dl) and severe liver
impairment (alanine aminotransferase 2837 U/L, aspar-
tate aminotransferase 3165 U/L).
The patient was considered to suffer from systemic
inflammatory response syndrome (SIRS) and was treated
with vigorous fluid resuscitation (crystalloids and colloids),
oseltamivir 150 mg/day and moxifloxacin (400 mg/day,
after appropriate cultures were obtained). A few hours
later, she was intubated and carried to the ICU, because of
refractory shock, where vasopressor therapy (noradrena-
line up to 2 μg/kg/min) was administered to maintain
mean arterial pressure ≥65 mmHg.
Arterial pressure wave form analysis (FloTrac/Vigileo
System), continuous ScVO2 and CVP monitoring were
used to estimate patient’s hemodynamics. After initial
fluid resuscitation, cardiac index, ScVO2 and CVP mea-
surements were 2.7 L/min/m
2, 75% and 13 mmHg, respec-
tively (mean values). Blood lactate levels were 4.8 mmol/L.
The ventilatory support consisted of controlled MV with
tidal volume 7 ml/kg and respiratory rate 15/min. Initial
plateau pressure was 16 cmH2O with respiratory system
compliance 58 ml/cmH2O.
The patient responded after 24 hours; noradrenaline was
tapered to 0.25 μg/kg/min and hydrocortisone (300 mg/
day) was added as adjunctive therapy. Additional
antibiotics included piperacillin/tazobactam (18 g/day) and
linezolide (1.2 g/day). Blood, urine and bronco-alveolar
lavage (BAL) cultures were negative. Real-time PCR for
influenza A/H1N1 virus (BAL specimen) was positive and
oseltamivir was administered at 300 mg/day.
In ICU, the clinical course was complicated by bacterial
co-infections 10 days after admission; septicaemia due to
carbapenem-resistant Klebsiella pneumoniae and ventila-
tor-associated pneumonia due to multi-drug resistant
Acinetobacter baumanii. Gentamicin and colistin were
administered, according to strain sensitivity, leading to
complete resolution of the lesions. She was extubated
after 19 days and transferred to the ward.
Concerning H1N1 virus, BAL rt-PCR was persistently
positive for 21 days. Oseltamivir was administered in high
doses (300 mg/day) for 28 days and was discontinued after
negative PCR.
The patient experienced a lupus flare (SLEDAI = 4, C3
= 65 mg/dl, C4 = 7.4 mg/dl), soon after extubation with
thrombocytopenia and severe haemolytic anemia. The
flare was successfully managed with steroids and intrave-
nous immunoglobulins (IVIGs). Her clinical condition
was complicated by severe critical illness polyneuropa-
thy/myopathy (CIP/CIM), managed with long term phy-
siotherapy. In four months, previous therapeutic regimen
was re-established and satisfactory performance status
was maintained.
Conclusions
Influenza A/H1N1 pandemic represents a global health
issue, as it was estimated to be the direct cause of over 600
million respiratory infections and over 50 million hospitali-
zations, until August 10
th, when WHO announced that
H1N1 was in post-pandemic period [6]. Immunosupression
is a well-defined risk factor for worse outcome in H1N1
disease. ARDS and secondary bacterial super-infections,
leading to septic shock and multiple organ failure are con-
sidered to be the primary causes of death [4,7]. However,
primary viral septic shock, especially by influenza, is rarely
reported in the literature [8-11].
The mortality pattern in SLE is reported to be biphasic;
major infections play an important role during the first
years of disease, while cardiovascular and other disease
complications account for most deaths in long-lasting
disease [12]. Viral infections, however, are not reported
to affect mortality in SLE [1,13].
Severe cardiovascular instability, as indicated by the
hemodynamic monitoring of the patient, with refractory
shock in H1N1 infection, has not been reported so far
in the literature. Acute lung injury and/or ARDS due to
H1N1 virus could not be identified, as initial chest X-
ray and thorax CT were normal and oxygenation was
not impaired (PaO2/FiO2≥350) throughout the disease
course.
Figure 1 Computed tomography of the thorax. Thorax CT was
normal on admission to the ICU, indicating the absence of overt
pulmonary involvement.
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were not diagnosed; serial blood, urine and BAL cultures
were negative. The therapeutic approach was that of con-
ventional septic shock, according to 2008 guidelines and
resulted in patient recovery [14].
Long lasting viral persistence, despite recommended
oseltamivir therapy, probably reflects a poor immune sta-
tus and defective natural and acquired antibacterial
immunity, due to several reasons. Patients with SLE are
considered to be immunocompromised either because of
the disease itself or due to the immunomodulating agents
used for disease management [15]. On the other hand,
splenectomy is not considered to represent a major risk
factor for viral infections.
Vaccination is suggested to be less effective in SLE, espe-
cially in the background of azathioprine treatment,
although measurement of antibody titers can only indir-
ectly assess the efficacy of vaccination [2]. Latest studies
supported that seroprotection after a single vaccination in
SLE patients was significantly reduced compared to
healthy controls [16]. The presented patient was vacci-
nated against seasonal influenza but not against H1N1
virus. Although recent reports suggest that CD8+ T cells
are able to cross react with H1N1 virus, they are function-
ally impaired [17].
The major complication in this patient, after ICU dis-
charge, was a disease flare (thrombocytopenia and hemoly-
tic anemia) along with CIP/CIM. The latter complicates
approximately 30-50% of ICU patients, particularly in
cases of multiple organ failure and septic shock [18]. The
pathophysiologic process behind CIP/CIM is not fully elu-
cidated; reactive oxygen intermediates, drug toxicity, ster-
oid therapy and poorly controlled hyperglycemia are
considered to be critical predisposing factors [18]. Treat-
ment options are not well validated, although intravenous
immunoglobulins seem to have a beneficial effect [19].
IVIGs were administered to this patient for managing
severe autoimmune haemolytic anemia and thrombocy-
topenia; their benefit in recovery from CIP/CIM can not
be assessed directly. However, IVIGs allowed quick ster-
oid tapering and, possibly, prevention of further nosoco-
mial infections.
To our knowledge, severe septic shock from influenza
A/H1N1 virus, without overt pulmonary involvement,
has not been reported in the literature. The authors of
this case report of special interest from many points of
view, feel it would be a positive step to share their
experience with experts in the field. Physicians’ aware-
ness and prompt and aggressive supportive treatment
are expected to optimize patient outcomes.
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